Présentation de l'entreprise
Tactile Systems Technology, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry to develop and provide solutions for treating underserved chronic diseases in the United States. The company's core offering includes the Flexitouch Plus system, a pneumatic compression device designed for the treatment of lymphedema, phlebolymphedema, lipedema, and venous insufficiency, addressing significant unmet medical needs. As of the latest data, the entity maintains a market capitalization of $549.19M and reported annual revenue of $329.52M, employing a workforce of 1086 individuals. These financial figures position the company as a mid-cap player with substantial operational scale, indicating a robust revenue base that supports its specialized focus on chronic disease management without the immediate pressure of being a large-cap conglomerate.
Santé financière
The company generated total revenue of $329.52M over the trailing twelve months, resulting in a net income of $19.09M and an EBITDA of $35.92M. The disparity between the $329.52M revenue and the $19.09M net income highlights a significant cost structure, where operating expenses, cost of goods sold, and taxes consume approximately 94.2% of top-line revenue before reaching the bottom line. The business demonstrated strong cash generation capabilities with free cash flow reaching $34.58M, providing the liquidity necessary for operational flexibility, potential share buybacks, or reinvestment in research and development without reliance on external financing. Profitability analysis reveals a gross margin of 75.9%, indicating highly efficient production or pricing power relative to direct costs, while an operating margin of 18.1% suggests moderate control over overhead expenses, culminating in a net profit margin of 5.8%. Regarding solvency, the firm holds $83.45M in cash against $15.96M in debt, supported by a debt-to-equity ratio of 7.29, which presents a mixed picture where low absolute leverage is offset by a high ratio relative to equity, suggesting a conservative approach to absolute debt loads but a specific capital structure dynamic. Liquidity is exceptionally strong with a current ratio of 4.03, signaling that the company possesses more than four times the current assets necessary to cover its short-term liabilities. Return metrics show a return on equity of 8.8% and a return on assets of 6.4%, indicating that management generates modest returns on the capital invested, which is typical for capital-intensive medical device sectors or companies in growth phases.
Évaluation de la valorisation
Valuation metrics indicate a trailing P/E ratio of 29.44 compared to a forward P/E of 16.31, implying that the market currently prices in a significant expansion of future earnings relative to historical performance. The price-to-book ratio stands at 2.47, suggesting that the stock trades at a premium of 147% over its book value, reflecting investor confidence in the brand's intangible assets and future growth potential rather than just its tangible asset base. Alternative valuation measures include a price-to-sales ratio of 1.67 and an EV/EBITDA of 13.20, which suggest the company is valued reasonably relative to its sales volume and earnings before interest, taxes, depreciation, and amortization, providing a different perspective on value that discounts high leverage or high cash balances. Price action over the last year has been volatile, with a 52-week high of $37.77 and a 52-week low of $8.61, meaning the current share price sits significantly below the yearly peak while remaining well above the floor of the trading range. The stock exhibits a beta of 0.99, indicating that its price volatility tracks the broader market almost one-for-one, suggesting it does not offer significant defensive characteristics nor aggressive upside potential relative to the S&P 500 in terms of systematic risk.
Growth & Income
Growth dynamics are robust, with revenue increasing by 21.0% year-over-year and earnings growing at a rate of 17.6%, indicating that profitability is expanding slightly slower than top-line sales, which often occurs during periods of market share gain or initial scale-up where margins may be under pressure before stabilizing. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it retains all earnings to fund organic growth initiatives, capital expenditures, or strategic acquisitions rather than distributing income to shareholders. This retention strategy aligns with the capital-intensive nature of the medical device industry, where reinvestment is critical for maintaining regulatory compliance and technological leadership. Overall, the company presents a high-growth profile with no current income distribution, prioritizing capital allocation toward expanding its footprint in treating chronic diseases rather than providing immediate yield to investors.